AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
Wall Street Bulls Look Optimistic About Adma Biologics ( ADMA ) : Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
Adma Biologics ( ADMA ) Just Flashed Golden Cross Signal: Do You Buy?
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Adma Biologics ( ADMA ) Crossed Above the 50-Day Moving Average: What That Means for Investors
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT reports narrower Q3 loss, boosts revenues on a Bristol Myers milestone, and advances in vivo gene-editing program with EDIT-401.
Wall Street Analysts Believe Adma Biologics ( ADMA ) Could Rally 108.5%: Here's is How to Trade
The consensus price target hints at a 108.5% upside potential for Adma Biologics (ADMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
Adma Biologics ( ADMA ) Q3 Earnings Match Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0.00% and +3.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
This Small-Cap Fund Just Bet $7 Million on Root's Comeback
California-based Palisades Investment Partners disclosed a new position in Root ( NASDAQ:ROOT ) valued at $7.3 million as of September 30, according to an SEC filing released Thursday.On Thursday, Palisades Investment Partners reported a new stake in Root, acquiring 81,716 shares in the third ...
This Small-Cap Fund Just Dumped $7 Million in ADMA Stock - Here's Why
On Thursday, California-based Palisades Investment Partners disclosed a complete exit from ADMA Biologics ( NASDAQ:ADMA ) , selling 398,647 shares for an estimated $7.3 million.According to a filing with the Securities and Exchange Commission released Thursday, Palisades fully liquidated its ...
ADMA Biologics Inc ( ADMA ) Is a Trending Stock: Facts to Know Before Betting on It
Adma Biologics (ADMA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street Analysts Think Adma Biologics ( ADMA ) Is a Good Investment: Is It?
According to the average brokerage recommendation (ABR), one should invest in Adma Biologics (ADMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025 - ADMA Biologics ( NASDAQ:ADMA )
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- ADMA Biologics, Inc. ( NASDAQ:ADMA ) ( "ADMA" or the "Company" ) , a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that ...
Adma Biologics ( ADMA ) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $15.6, denoting a +2.77% move from the preceding trading day.
Here's Why Adma Biologics ( ADMA ) Fell More Than Broader Market
Adma Biologics (ADMA) closed at $14.56 in the latest trading session, marking a -3.51% move from the prior day.
Adma Biologics ( ADMA ) Is Considered a Good Investment by Brokers: Is That True?
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Adma Biologics ( ADMA ) Stock Moves -1.36%: What You Should Know
In the latest trading session, Adma Biologics (ADMA) closed at $14.54, marking a -1.36% move from the previous day.
Why Adma Biologics ( ADMA ) Outpaced the Stock Market Today
Adma Biologics (ADMA) concluded the recent trading session at $15.05, signifying a +2.66% move from its prior day's close.
Is It Worth Investing in Adma Biologics ( ADMA ) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Adma Biologics ( ADMA ) Declines More Than Market: Some Information for Investors
In the latest trading session, Adma Biologics (ADMA) closed at $15.32, marking a -2.17% move from the previous day.
Are Options Traders Betting on a Big Move in ADMA Biologics Stock?
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Adma Biologics ( ADMA ) Stock Dips While Market Gains: Key Facts
In the latest trading session, Adma Biologics (ADMA) closed at $15.91, marking a -1.55% move from the previous day.
Adma Biologics ( ADMA ) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed the most recent trading day at $15.3, moving 5.03% from the previous trading session.
Is Adma Biologics ( ADMA ) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Adma Biologics ( ADMA ) Q2 Revenue Up 14%
Adma Biologics ( NASDAQ:ADMA ) , a plasma-derived biologics manufacturer focused on immunotherapies, released its earnings for Q2 2025 on August 6, 2025. The quarter showed continued revenue growth, with GAAP total revenue of $122.0 million, with total revenue ( GAAP ) reaching $122.0 million, ...
Adma Biologics ( ADMA ) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of +7.14% and +0.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has fallen 10.9% since its last report. The company recently reported that it has 14.47 million shares sold short, which is 7.44% of all regular shares that are available for trading.
Adma Biologics ( ADMA ) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET ...
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - ADMA Biologics ( NASDAQ:ADMA )
RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 ( GLOBE NEWSWIRE ) -- ADMA Biologics, Inc.
Adma Biologics ( ADMA ) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Brokers Suggest Investing in Adma Biologics ( ADMA ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics ( ADMA ) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) concluded the recent trading session at $17.13, signifying a +2.39% move from its prior day's close.
Adma Biologics ( ADMA ) Declines More Than Market: Some Information for Investors
In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day.
Adma Biologics ( ADMA ) Outperforms Broader Market: What You Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.
Wall Street Bulls Look Optimistic About Adma Biologics ( ADMA ) : Should You Buy?
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has fallen 3.53% since its last report. The company recently reported that it has 13.81 million shares sold short, which is 7.1% of all regular shares that are available for trading.
Adma Biologics ( ADMA ) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.
Implied Volatility Surging for ADMA Biologics Stock Options
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
